Daniela Ramos
Baylor College of Medicine
5 Papers
4 Citations
Daniela Ramos is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Medicine & Cytotoxic T cell. The author has an hindex of 1, co-authored 3 publications.
Chat about Author
Papers
Inhibition of CDK4/6 Overcomes Primary Resistance to PD-1 Blockade in Malignant Mesothelioma
Hee Jin Jang,Cynthia Y. Truong,Eric M. Lo,Hudson M. Holmes,Daniela Ramos,Maheshwari Ramineni,Jangsoon Lee,Daniel Ying Wang,Massimo Pietropaolo,Robert T. Ripley,Bryan M. Burt,Hyun-Sung Lee +11 more
TL;DR: In this paper, a novel therapeutic target, CDK4/6, was identified to overcome primary resistance to checkpoint immunotherapy in malignant pleural mesothelioma (MPM) patients.
5
Prognostic Role of Programmed Cell Death 1 Ligand 1 in Resectable Pleural Mesothelioma.
Hyun-Sung Lee,Masatsugu Hamaji,Nihanth Palivela,Hee Jin Jang,Taylor Splawn,Daniela Ramos,Alice K. Lee,Alice K. Lee,Anjali C. Raghuram,Maheshwari Ramineni,Christopher I. Amos,R. Taylor Ripley,Bryan M. Burt +12 more
TL;DR: Tumor PD-L1 expression is a prognostic biomarker in patients undergoing surgical resection for MPM and may be useful in perioperative decision making.
A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma.
Hyun-Sung Lee,Hee Jin Jang,Maheshwari Ramineni,Daniel Y. Wang,Daniela Ramos,Jong Min Choi,Taylor Splawn,Monica Espinoza,Michelle Almarez,Leandria Hosey,Eunji Jo,Susan G. Hilsenbeck,Christopher I. Amos,Robert T. Ripley,Bryan M. Burt +14 more
TL;DR: The results of a phase 2, randomized, window-of-opportunity trial of neoadjuvant durvalumab plus tremelimumab followed by surgery in patients with resectable malignant pleural mesothelioma (MPM) were reported in this paper .
Transcriptome-based molecular subtyping of non–small cell lung cancer may predict response to immune checkpoint inhibitors
Hee Jin Jang,Hee Jin Jang,Hyun-Sung Lee,Daniela Ramos,In Kyu Park,Chang Hyun Kang,Bryan M. Burt,Young Tae Kim,Young Tae Kim +8 more
TL;DR: Molecular stratification by transcriptome sequencing data in non-small cell lung cancer identifies distinct immunomolecular subtypes that predict the response to programmed cell death 1 blockade.
Therapeutic targeting of macrophage plasticity remodels the tumor-immune microenvironment.
Hee Jin Jang,Hyun-Sung Lee,Wendong Yu,Maheshwari Ramineni,Cynthia Y. Truong,Daniela Ramos,Taylor Splawn,Jong Min Choi,Sung Yun Jung,Ju-Seog Lee,Daniel Y. Wang,Joel M. Sederstrom,Massimo Pietropaolo,Farrah Kheradmand,Christopher I. Amos,Thomas M. Wheeler,R. Ripley,Bryan M. Burt +17 more
TL;DR: Comprehensive investigation of mouse and human LUAD using single-cell proteomics platforms showed that LUAD progression is associated with spatiotemporal evolution of tumor-associated macrophages in the tumor-immune microenvironment, which governs tumor response to immunotherapy.